Fluconazole vs Itraconazole-Flucytosine Association in the Treatment of Esophageal Candidiasis in AIDS Patients: A Double-blind, Multicenter Placebo-Controlled Study

Chest

Volumn 110, Issue 6, 1996, Pages 1507-1514

  Barbaro, Giuseppe ^a,c   Barbarini, Giorgio ^b   Di Lorenzo, Gabriella ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c NONE   (Italy)

Author keywords

AIDS; Candidiasis; Flucytosine; Flueonazole; Itraconazole

Indexed keywords

FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EPIGASTRIC PAIN; ESOPHAGITIS; FEMALE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CANDIDIASIS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESOPHAGITIS; ESOPHAGOSCOPY; FEMALE; FLUCONAZOLE; FLUCYTOSINE; HUMANS; ITRACONAZOLE; MALE; TREATMENT OUTCOME;

EID: 0030451777     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.110.6.1507     Document Type: Article

References (26)

1. Rondanelli EG. AIDS: clinical and laboratory atlas. Pavia: Edizioni Medico-Scientifiche, 1989; 86-91
2. Deschamps MM, Pape JW, Verdier RI, et al. Treatment of Candida esophagitis in AIDS patients. Am J Gastroenterol 1988; 83:20-1
3. Connolly GM, Hawkins D, Harcourt-Webster JN, et al. Oesophageal symptoms, their causes, treatment and prognosis in patients with the acquired immunodeficiency syndrome. Gut 1989; 30:1033-39
4. Smith DE, Midgley J, Allan M, et al. Itraconazole vs ketoconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV. AIDS 1991; 5:1367-71
5. Laine L, Dretler RH, Conteas CN, et al. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS: a randomized trial. Ann Intern Med 1992; 117:655-60
6. Barbaro O, Di Lorenzo G. Comparison of therapeutic activity of fluconazole and itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Ital J Gastroenterol 1995; 27:175-80
7. Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole vs flucytosine in the treatment of esophageal candidiasis in AIDS patients: a double-blind, placebo-controlled study. Endoscopy 1995; 27:377-83
8. Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Gut 1995; 37(S2):A6-7
9. Kodsi BE, Wicremesinghe PC, Kozinn PJ, et al. Candida esophagitis: a prospective study of 27 cases. Gastroenterology 1976; 71:715-19
10. Armitage P, Berry G. Statistical methods in medical research. 3rd ed. Oxford. England: Blackwell Scientific, 1994
11. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16:1141-54
12. Bennett JE. Antifungal agents. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and practice of infections diseases. 3rd ed. New York: Churchill Livingstone, 1990; 361-70
13. Diasio RB. Bennett JE, Myers CE. Mode of action of 5-fluorocytosine. Biochem Pharmacol 1978; 27:703-07
14. Bonacini M, Young T, Laine L. The causes of esophageal symptoms in human immunodeficiency virus infection: a prospective studs of 110 patients. Arch Intern Med 1991; 151:1567-72
15. Grant SM, Clissold SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetics properties, and therapeutic potential in superficial and systemic myocoses. Drugs 1990; 39:877-916
16. Phillips P, Fetchick R, Weisman I, et al. Tolerance and efficacy of itraconazole in treatment of systemic myocoses: preliminary results. Rev Infect Dis 1987: 9(suppl 1):S87-93
17. Just-Nubling G, Gentschew G, Dohle M, et al. Fluconazole in the treatment of oropharyngeal candidosis in HIV-positive patients. Mycoses 1990; 33:435-40
18. Saag MS, Dismukes WE. Azole antifungal agents: empliasis on new triazoles. Antimicrob Agents Chemother 1988; 32:1-8
19. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330:263-72
20. Lake-Bakaar G, Ouadros E, Beidas S, et al. Gastric secretory failure in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988; 109:502-04
21. Lake-Bakaar G, Tom W, Lake Bakaar D, et al. Gastropathy and ketocouazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988; 109:471-73
22. Smith D, Woestenborghs R, Heykants J, et al. The pharmacokinetics of oral itraconazole in AIDS patients. Proceedings of the Seventh International Conference on AIDS, Florence, June 16-21, 1991, 225 [abstract] (WB 2174)
23. Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insight into safety, phannacokinetics, and antifungal therapy. Clin Infect Dis 1992: 15:1003-18
24. Cameron ML, Schell WA, Bruch S, et al. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type I. Antimicrob Agents Chemother 1993; 37:2449-53
25. Ruluike M, Eigler A, Engelmann K, et al. Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole. Infection 1994; 22:132-36
26. Scalarone GM, Mikami Y, Kurita N, et al. In vitro comparative evaluation of the postantifungal effect: synergistic interaction between flncytosine and fluconazole against Candida albicans. Mycoses 1991; 34:405-10